Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate AtriCure, Inc. before investing.

In this article, we go over a few key elements for understanding AtriCure, Inc.’s stock price such as:

• AtriCure, Inc.’s current stock price and volume
• Why AtriCure, Inc.’s stock price changed recently
• Upgrades and downgrades for ATRC from analysts
• ATRC’s stock price momentum as measured by its relative strength

About AtriCure, Inc. (ATRC)

Before we jump into AtriCure, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula’s to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Want to learn more about AtriCure, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about AtriCure, Inc..

AtriCure, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, AtriCure, Inc.’s stock price was $37.760.

AtriCure, Inc. is down 5.95% from its previous closing price of $40.150.

During the last market session, AtriCure, Inc.’s stock traded between $37.440 and $39.410. Currently, there are approximately 48.67 million shares outstanding for AtriCure, Inc..

AtriCure, Inc.’s price-earnings (P/E) ratio is currently at 179.0, which is high compared to the Health Care Equipment & Supplies industry median of 31.1. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

AtriCure, Inc. Stock Price History

AtriCure, Inc.’s (ATRC) price is currently up 34.95% so far this month.

During the month of July, AtriCure, Inc.’s stock price has reached a high of $41.290 and a low of $28.200.

Over the last year, AtriCure, Inc. has hit prices as high as $43.180 and as low as $25.360. Year to date, AtriCure, Inc.’s stock is down 4.55%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused AtriCure, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded AtriCure, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate AtriCure, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on AtriCure, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

AtriCure, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about AtriCure, Inc. (ATRC) by visiting AAII Stock Evaluator.

Relative Price Strength of AtriCure, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, AtriCure, Inc. has a weighted four-quarter relative price strength of 4.58%, which translates to a Momentum Score of 69 and is considered to be Strong.

Want to learn more about how AtriCure, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

AtriCure, Inc. Stock Price: Bottom Line

As of July 31, 2026, AtriCure, Inc.’s stock price is $37.760, which is down 5.95% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like AtriCure, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.